News

News stories

DNA strand

FDA approves trial to advance pioneering treatment for Hereditary Spastic Paraplegia (HSP)

The US Food and Drug Administation (FDA) has approved BlackfinBio Limited’s Phase 1/2 clinical trial for its novel adeno-associated virus (AAV) gene therapy targeting Hereditary Spastic Paraplegia (HSP) Type 47 (SPG47).
DNA strands

Sheffield spinout takes major step towards advancing pioneering treatments for Hereditary Spastic Paraplegia (HSP)

BlackfinBio Limited is a spinout company from the ±¬ÁϹ«Éç set to pioneer novel therapies for rare genetic neurological diseases.

Image of motor neurones

Groundbreaking EXPERTS-ALS study for MND treatments

The EXPErimental medicine Route To Success in ALS (EXPERTS-ALS) project aims to rapidly screen potential drugs for evidence that they can slow down damage to the nervous system occurring in people with motor neuron disease
Professor Mimoun Azzouz holding a petri dish

Comment: Turning the biggest disappointment of a career into a new era for UK gene therapy manufacturing

Professor Mimoun Azzouz discusses career challenges before opening the Gene Therapy Innovation and Manufacturing Centre (GTIMC) at the ±¬ÁϹ«Éç.
Neuron cells system. Conceptual medical image. Glowing synapse. Healthcare concept.

New AI model helps discover causes of motor neurone disease

Scientists have developed a new machine learning model for the discovery of genetic risk factors for diseases such as Motor Neurone Disease (MND).
atherosclerosis in brain

Heart disease causes early brain dysfunction and can treble key Alzheimer’s protein

Heart disease can directly cause brain dysfunction early on which could lead to dementia and can treble the amount of an Alzheimer’s protein in the brain, say scientists.
Professor Christopher McDermott

Congratulations to Professor Christopher McDermott for being awarded the prestigious Research Professorship for his work on motor neuron disease

The professorship will enable Chris to improve the care that people living with motor neurone disease (MND) receive, and help more patients living with this terminal neurodegenerative disease take part in clinical trials.
Professor Dame Pamela Shaw

Sheffield scientists welcome £50 million investment to accelerate MND research

Sheffield scientists have welcomed the government’s £50 million investment to accelerate motor neurone disease (MND) research to bring effective treatments for patients living with the terminal neurodegenerative disease.